| Risk Factors for Cardiovascular Events in Japanese Patients Treated with Fluvastatin from the Long-Term Event Monitoring (LEM) Study. | |
| | |
MedLine Citation:
|
PMID: 21824105 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Objective: Long-term event monitoring (LEM) study was designed to evaluate the long-term lipid-lowering efficacy and safety of fluvastatin in Japanese patients with hypercholesterolemia. From LEM study, the present study focused on the impact of risk factors such as diabetes after statin treatment on event prevention. Methods: In LEM study, patients (n=21,139) who started fluvastatin between 2000/4/1 and 2002/3/31 in Japan were prospectively registered and followed up for 3 years (secondary prevention cohort) or 5 years (primary prevention cohort). Results: Of the patients registered, 19,084 were included in this sub-analysis. In the secondary prevention, complication of cardiac disease demonstrated 8.27- and 2.89-fold higher incidence in cardiac events and cerebral events, respectively as compared to primary prevention (P<0.001). Complication of cerebrovascular disease also demonstrated a 2.22- and 5.29-fold higher incidence in cardiac events and cerebral events (P<0.01 and P<0.001, respectively). Presence of DM in patients without complication significantly increased the incidence in both cardiac events (2.37) and cerebral events (2.15) as compared to non-DM patients for primary prevention (P<0.001 and P<0.01, respectively). For the secondary prevention, DM Patients with complication of cardiac disease showed a significantly higher incidence in both cardiac events (1.59) and cerebral events (3.79) as compared to non-DM patients (P<0.05 and P<0.01, respectively). In contrast, DM Patients with complication of cerebrovascular disease showed a significantly higher incidence in cerebral events (2.58, P<0.05), but not cardiac events, as compared to non-DM patients. Similarly, presence of hypertension significantly increased the incidence in both cardiac (1.64) and cerebral events (1.81) for primary prevention (P<0.01 and P<0.05, respectively). For the secondary prevention, hypertension in patients with complication of cardiac or cerebrovascular disease did not affect incidence in both cardiac and cerebral events. In the patients without complication, high triglycerides and low HDL cholesterol, but not LDL cholesterol, increased cerebral events, while only LDL cholesterol significantly increased cardiac events. For the secondary prevention, high triglycerides or low HDL cholesterol, but not LDL cholesterol, significantly increased the relative risk of cardiac events in the patients with complication of cardiac disease. Conclusion: LEM study, a large-scale prospective study of long-term fluvastatin treatment for hypercholesterolemia in Japanese patients, demonstrated high impact of complications such as DM and hypertension as well as high triglycerides or low HDL cholesterol on cardiac and cerebral events. After long-term statin treatment, the control of other factors rather than LDL cholesterol might be important to avoid cardiac and cerebral events. |
| | |
Authors:
|
Ryuichi Morishit; Hiroshige Itakuraa; Noriaki Nakaya; Masayuki Yoshida; Masato Odawara; Atsuhiro Ichihara; Kyoichi Mizuno |
Related Documents
:
|
21936615 - Progressive capillary loss over a decade in patients with systemic sclerosis, in partic... 11075985 - Acute pancreatitis secondary to pancreatic carcinoma. study group participants. 17198185 - Comparison and validation of scoring systems in a cohort of patients treated for biliar... 11242485 - Blood sulfur-amino acid concentration reflects an impairment of liver transsulfuration ... 20975055 - Clinical features of facioscapulohumeral muscular dystrophy 2. 20569565 - Heparin or local thrombolysis in the management of cerebral venous sinus thrombosis? |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-8-9 |
Journal Detail:
|
Title: Current vascular pharmacology Volume: - ISSN: 1875-6212 ISO Abbreviation: - Publication Date: 2011 Aug |
Date Detail:
|
Created Date: 2011-8-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101157208 Medline TA: Curr Vasc Pharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Clinical Gene Therapy, Osaka University, Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. morishit@cgt.med.osaka-u.ac.jp. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment of Cardiovascular Calcification in Uremi.
Next Document: Progress of Computer-Aided Drug Design (CADD) of Proteasome Inhibitors.